Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program

Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrocal, Alfonso, Arance, Ana, Lopez Martin, Jose Antonio, Soriano, Virtudes, Muñoz, Eva, Alonso, Lorenzo, Espinosa, Enrique, Lopez Criado, Pilar, Valdivia, Javier, Martin Algarra, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
ORIGINAL ARTICLES: Clinical research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457498/
https://www.ncbi.nlm.nih.gov/pubmed/25046550
http://dx.doi.org/10.1097/CMR.0000000000000108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457498/
https://www.ncbi.nlm.nih.gov/pubmed/25046550
http://dx.doi.org/10.1097/CMR.0000000000000108

Ejemplares similares